tecovirimat + sevelamer carbonate

This entry refers to the **coadministration** of tecovirimat (an antiviral for orthopoxviruses such as smallpox) and sevelamer carbonate (a phosphate binder for hyperphosphatemia in chronic kidney disease), specifically as tested in single-dose pharmacokinetic interaction studies in healthy adults. Tecovirimat acts by inhibiting the orthopoxvirus VP37 protein, preventing production of egress-competent enveloped virions, thus blocking viral spread. Sevelamer carbonate binds phosphate in the gastrointestinal tract. Coadministration increases tecovirimat systemic exposure (Cmax, AUC) without a clinically significant pharmacodynamic interaction but may require monitoring for adverse effects due to higher tecovirimat levels[1][2][3][4][5].

Other names

tecovirimatsevelamer carbonate